登录
| 企业文档数据库
  • 首页
  • 医学材料
    • 指南共识
    • 循证证据
    • 推荐观点
    • 临床项目
  • 产品信息/适应症
    • 宁泌泰胶囊
    • 夏枯草口服液
    • 苦参凝胶
    • 坤泰胶囊
    • 注射用西维来司他钠
    • 佐愈
    • 蒂诺安
    • 匹瑞
    • 卫达甘
  • 市场材料
    • 应用场景
    • 推荐观点
    • 市场活动
    • 绿卡
    • 事业部医学支持
    • 案例中心
  • 科室及医护人员
    • 内科
    • 外科
    • 重点科室
    • 医护群体
登录
  1. 首页
  2. 医学材料
  3. 循证证据
  4. 产品信息/适应症
  5. 汇伦医药
  6. 注射用西维来司他钠
  7. 科室及医护人员
  8. 外科
  9. 重点科室
  10. 胃肠外科
  11. ICU
  12. 急诊
  13. 普外科
  14. 综合ICU
  15. 急诊ICU
  16. 正文

Early administration of sivelestat, the neutrophil elastase inhibitor, in adults for acute lung injury following gastric aspiration

收藏
文章来源:
摘要:Gastric aspiration is the major cause of acute lung injury (ALI) and acute respiratory distress syndrome. Aspiration-induced ALI is believed to be, at least in part, facilitated by neutrophil-derived mediators and toxic molecules. We conducted a prospective cohort study based on the hypothesis that sivelestat, a specific neutrophil elastase inhibitor, is effective for treating ALI following gastric aspiration. Forty-four ALI patients who showed evidence of aspiration were observed within 12 h before intensive care unit admission and who had been mechanically ventilated within 12 h after admission were included in this study. Lung injury score (LIS) and PAO2/FiO2 (P/F) ratio on day 7 were defined as the primary outcomes of the study. Twenty-three patients were assigned to the sivelestat group and 21 to the control group. In univariate analyses, the proportions of patients with LIS lower than 1.0 on day 7 and a P/F greater than 300 on day 7 were significantly higher in the sivelestat group than in the control group (60.9% vs. 26.3%, P = 0.03; 87.0% vs. 36.8%, P = 0.001). In the logistic regression model, the use of sivelestat was an independent predictor for LIS lower than 1.0 on day 7 (relative risk, 7.4; 95% confidence interval [CI], 1.51-36.48) and for a P/F ratio higher than 300 on day 7 (relative risk, 18.5; 95% CI, 2.72-126.46). In the Cox proportional hazards model, the use of sivelestat was associated with a lower cumulative proportion of patients who received mechanical ventilation during the initial 14 days (hazard ratio, 2.6; 95% CI, 1.17-5.55).
标签: 创伤+中毒+吸入 产品信息/适应症 汇伦医药 西维来司他钠 ICU 外科 急诊
查看数:135
发布时间:2024-09-04 邹文成
公开


文档附件清单
  • 附件1: 创伤-中毒-吸入2-Early Administration of Sivelestat, the Neutrophil Elastase Inhibitor, in Adults for Acute Lung Injury Following Gastric Aspiration.pdf 下载附件
评论
0
      医学材料热门文章
      • 1. 急性呼吸窘迫综合征抗炎治疗中中性粒细胞弹性蛋白酶抑制剂急诊应用专家共识
      • 2. A New Global Definition of Acute Respiratory Distress Syndrome
      • 3. 中国创伤性脊髓损伤流行病学和疾病经济负担的系统评价
      • 4. 西维来司他钠联合俯卧位通气在急性肺损伤/急性呼吸窘迫综合征中的疗效评价
      • 5. 西维来司他钠治疗ARDS患者的效果及其应用价值
      • 6. The Protective Effects of Sivelestat Sodium on the Basis of Corticosteroid Therapy in Patients With Moderate-to-Severe Acute Respiratory Distress Syndrome
      • 7. 西维来司他钠对颅脑损伤合并ARDS患者的一项多中心、前瞻性、双盲、随机对照试验
      • 8. 西维来司他钠在ICU不同疾病合并ARDS患者中的应用效果
      • 9. 西维来司他钠在中国重症肺炎患者中的群体药代动力学
      • 10. 有创-无创序贯通气疗法联合美罗培南、西维来司他钠治疗急性呼吸窘迫综合征的效果及对炎性因子水平的影响
      热门文章
      • 1. 急性呼吸窘迫综合征抗炎治疗中中性粒细胞弹性蛋白酶抑制剂急诊应用专家共识
      • 2. A New Global Definition of Acute Respiratory Distress Syndrome
      • 3. 中国创伤性脊髓损伤流行病学和疾病经济负担的系统评价
      • 4. 西维来司他钠联合俯卧位通气在急性肺损伤/急性呼吸窘迫综合征中的疗效评价
      • 5. 西维来司他钠治疗ARDS患者的效果及其应用价值
      • 6. 希为纳EDA
      • 7. The Protective Effects of Sivelestat Sodium on the Basis of Corticosteroid Therapy in Patients With Moderate-to-Severe Acute Respiratory Distress Syndrome
      • 8. 希为纳围术期病例库(心外/神外/胸外/肝胆外)
      • 9. 西维来司他钠对颅脑损伤合并ARDS患者的一项多中心、前瞻性、双盲、随机对照试验
      • 10. 西维来司他钠在ICU不同疾病合并ARDS患者中的应用效果

      版权所有 © 上海汇伦医药股份有限公司 沪ICP备17025706号-2